This commentary on a case considers how clinicians can help nonbinary patients minimize potential harms of psychedelics.

Reconsider regulatory and clinical frameworks for prescribing long-term opioid therapy for pain and prescribing opioids to treat OUD.

Dr Kelly Gillespie joins Ethics Talk to discuss her article, coauthored with Dr Taleed El-Sabawi: “When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?”

Dr Jim Withers and Dave Lettrich join Ethics talk to discuss how street outreach programs help mitigate harms of drug use among people experiencing homelessness.

Evidence of harm reduction interventions’ morbidity and mortality benefits is abundant and of high quality.

Becoming callous, bitter, or resentful are harms we can suffer when grieving losses, especially at epidemic scale.

Dr Elizabeth Salisbury-Afshar joins Ethics Talk to discuss her article, coauthored with Drs Catherine J. Livingston and Ricky N. Bluthenthal: “How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?”

Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary.

Equity requires full access to evidence-based OUD care, housing stability, and education and employment opportunities.

Dr Donald Egan joins Ethics Talk to discuss his article, coauthored with Drs Adriane M. dela Cruz, Sarah E. Baker, and John Z. Sadler: “When Are ‘Paraphernalia’ Critical Medical Supplies?”